In a groundbreaking clinical study, DBV Technologies has revealed promising results for its innovative peanut allergy treatment, the Peanut Patch. The study, conducted over two years, demonstrated a significant reduction in accidental allergic reaction rates among participants. This news was shared as part of DBV’s presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. The Peanut Patch is designed to gently desensitize children aged 4 to 11 years to peanut allergens, providing a novel and non-invasive approach to allergy management. These findings highlight the potential of the Peanut Patch in transforming the lives of many individuals with peanut allergies by reducing the frequency and severity of accidental exposures. As DBV Technologies continues its mission to address unmet medical needs in allergy treatment, this new data reinforces the therapeutic promise of the Peanut Patch.
Stock TitanNew data shows cost of living pressures impacting charities and communities
June 11, 2026
Recent data from the Australian Charities and Not-for-profits Commission (ACNC) reveals that rising cost of living pressures are significantly impacting charities and communities across Australia.